Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant.
Lorenzo LazzariChiara OltoliniFabio CiceriFabio GiglioPublished in: BMJ case reports (2021)
We describe the case of a 45-year-old man affected by T-cell acute lymphoblastic leukaemia and diagnosed with COVID-19 early after an allogeneic haematopoietic stem cell transplant. The infectious disease was characterised by a severe and prolonged course, further complicated by a spontaneous pneumomediastinum and pneumopericardium. We successfully treated this patient with the antiviral drug remdesivir associated with two courses of COVID-19 convalescent plasma. This case report represents a good example of the typical clinical course of COVID-19 in severely immunosuppressed patients and gives evidence that in this population only a prompt treatment directed towards viral clearance can face the absence of a valid immune reactivity.
Keyphrases
- sars cov
- coronavirus disease
- stem cells
- case report
- stem cell transplantation
- infectious diseases
- respiratory syndrome coronavirus
- end stage renal disease
- bone marrow
- ejection fraction
- drug induced
- newly diagnosed
- liver failure
- respiratory failure
- emergency department
- prognostic factors
- low dose
- mesenchymal stem cells
- patient reported outcomes
- hematopoietic stem cell
- combination therapy
- acute respiratory distress syndrome